Using a murine model of disseminated infection caused by Trichosporon asahii, we have evaluated the efficacies of amphotericin B (AMB; 1 mg/kg of body weight/day), fluconazole (FLC; 20 mg/kg/twice a day), and micafungin (MFG; 5 mg/kg/twice a day). We tested these drugs alone and in combination (MFG with AMB and MFG with FLC). MFG with AMB showed a synergistic effect and demonstrated a higher degree of efficacy in prolonging survival and reducing the kidney fungal burden than either agent alone. The combination MFG with FLC was able to reduce significantly the kidney fungal burden in comparison to that achieved with either drug administered alone.
Disseminated trichosporonosis is a severe infection that mainly affects immunocompromised patients, particularly those with hematological malignancies (13, 20, 21, 23) . Trichosporon asahii is the most common species that causes disseminated trichosporonosis (10, 11, 13, 16) . Penetration of this fungus into the body is facilitated by indwelling vascular catheters, drainage tubes, burns, or microbial translocation from the intestinal mucosa (20, 21) . One of the most important problems inherent to these infections is that Trichosporon is often morphologically confused with Candida spp. Such misidentification could lead to the administration of inappropriate therapy because Trichosporon is generally less susceptible to amphotericin B (AMB), the drug usually used empirically for the treatment of suspected yeast infections (19) . Up to now the use of a drug alone to treat systemic trichosporonosis has not been completely satisfactory (7, 22) . Despite the administration of AMB or fluconazole (FLC) (1, 5, 7, 9, 13, 22) , this infection is almost always fatal, with the mortality rate from trichosporonosis being even higher than that from candidiasis (19) . However, the usefulness of combined therapy for the treatment of this infection has not yet been extensively investigated. The combination AMB with FLC has demonstrated some beneficial effects for the experimental treatment of a murine infection caused by T. beigelii (2, 15) , which is no longer an accepted name, as it has been used to refer to different currently accepted species of this genus.
In this study we have evaluated the activity of the new echinocandin micafungin (MFG) in combination with FLC or AMB in a murine model of disseminated trichosporonosis. Although it has been demonstrated that MFG alone is not active against T. asahii in vitro (18) , it is unknown whether this drug in combination with azoles or polyenes could be effective, as it has proven to be in experimental infections caused by Candida or Aspergillus (4, 12) .
MATERIALS AND METHODS

Fungi.
Two clinical isolates of T. asahii, isolates IHEM 17910 and IHEM 17911, from blood cultures of patients with medullar aplasia posthepatitis and acute lymphocytic leukemia, respectively, were used in this study. The isolates were stored at Ϫ80°C in potato dextrose broth with glycerol, and prior to testing they were subcultured on Sabouraud dextrose agar (SDA) at 35°C. On the day of infection, 24-h cultures on SDA were suspended in sterile saline and filtered through sterile gauze to remove clumps of cells or hyphae. The resulting suspensions, which contained Ն95% conidial forms (arthroconidia and blastoconidia), were adjusted to the desired inoculum size with a hemocytometer. Dilutions of the original suspension were cultured on SDA plates to confirm the counts determined with the hemocytometer.
In vitro studies. The MICs of MFG, AMB, and FLC for the two strains used in the study were determined by a broth microdilution method, according to the NCCLS guidelines for yeasts (17) . Antifungal interactions were studied by a checkerboard microdilution method (8) .
Animals. Male OF1 mice (Charles River, Criffa S.A., Barcelona, Spain) with a mean weight of 30 g were used. The animals were housed in standard boxes with corncob bedding and had free access to food and water. All animal care procedures were supervised and approved by the Universitat Rovira i Virgili Animal Welfare Committee.
Drugs. AMB was purchased as Fungizona (Squibb Industrial Farmaceutica S. A., Barcelona, Spain), FLC was obtained from Pfizer Inc. (Madrid, Spain), and MFG was from Fujisawa Pharmaceutical Co. Ltd (Osaka, Japan).
Immunosuppression. Mice were immunosuppressed by a single intraperitoneal (i.p.) injection of 200 mg of cyclophosphamide (Genoxal; Laboratorios Funk S. A., Barcelona, Spain) per kg of body weight plus a single intravenous injection of 150 mg of 5-fluorouracil (Fluoro-uracil; Productos Roche S. A., Madrid, Spain) per kg on the day of infection.
Infection and therapy. For the survival studies, groups of 20 mice each were established for infection with each strain and for each treatment. The mice were challenged with 6 ϫ 10 6 CFU in 0.2 ml injected into the lateral tail vein. Preliminary experiments with both strains (data not shown) demonstrated that this concentration of fungal elements was the optimal dose for producing an acute infection, with 80% of the animals dying within 10 days of infection. Control animals received no treatment. Different groups were treated as follows: AMB at 1 mg/kg of body weight/dose given i.p. once daily (QD), FLC at 20 mg/kg of body weight/dose given orally twice daily (BID), MFG at 5 mg/kg of body weight/dose given subcutaneously (s.c.) BID, MFG given s.c. (5 mg/kg BID) plus FLC given orally (20 mg/kg BID), and MFG given s.c. (5 mg/kg/BID) plus AMB given i.p. (1 mg/kg QD). All treatments began 1 h after challenge, and the therapy lasted for 4 days. The mice in each experiment were checked daily for 30 days after challenge. All the experiments were performed as a single study, with the exception that the combined therapy for the treatment of infection caused by strain IHEM 17911 was done separately. In this case the study with the control was repeated to confirm the reproducibility of the results.
Tissue burden studies. Five groups of 10 mice each infected with strain IHEM 17910 were used for the tissue burden studies. Three groups were treated with the same monotherapies indicated above, and in a different experiment two groups were treated with the combinations MFG with AMB and MFG with FLC, respectively, at the doses described above. A control group of 10 untreated animals was included in each experiment to confirm the reproducibility of the results. For all treatments, therapy began 1 h after challenge and lasted for 4 days. All mice were killed 1 day after the completion of treatment. The livers, spleens, and kidneys were aseptically removed; and portions of each organ were homogenized in 1 ml of sterile saline. Serial 10-fold dilutions of the homogenates were plated on SDA and incubated 48 h at 35°C, and the numbers of CFU per gram of tissue were calculated.
Histological studies. For the histopathology studies, a portion of each specimen was placed in 10% buffered formalin. The organs were sectioned in paraffin blocks; and for microscopic observation, sections of 3 m were stained with periodic acid-Schiff, hematoxylin-eosin, and Grocott methenamine silver stains.
Statistics. The mean survival time (MST) was estimated by the Kaplan-Meier method, and the MSTs among the groups were compared by the log-rank test. In the tissue burden studies the colony counts were analyzed by a parametric method that consisted of an analysis of variance. Calculations were made by using SPSS software for Windows (version 11.0).
FIG. 1. Cumulative mortality of mice infected with T. asahii IHEM 17910 (A) or T. asahii IHEM 17911 (B) and treated with MFG and AMB.
All the experiments were performed as a single study with the exception of the combined therapy against strain IHEM 17911, which was done separately. The experiment with the control group was repeated, and the results were not different from the previous ones. In this case the curve is the result of the mean for both data sets. 
RESULTS
In vitro results. The antifungal activities of the drugs tested and the interactions among them are shown in Table 1 . The MICs of the drugs for the two strains were identical, i.e., Ͼ64 g/ml for MFG, 1 g/ml for AMB, and 4 g/ml for FLC. The combination MFG with AMB showed a synergistic interaction against the two strains tested (fractional inhibitory concentration indices [FICIs], 0.50 and 0.25, respectively), while the combination MFG with FLC showed an indifferent interaction against the two strains (FICIs ϭ 0.5009) (14) .
In vivo results. The effects of the different treatments on mouse survival are shown in Fig. 1 and 2 and Table 2 . In tests with both strains, treatment with the combination MFG with AMB resulted in survival rates higher than those for the control group (P Ͻ 0.0001) and the group treated with MFG or AMB alone (P ϭ 0.0025 and P ϭ 0.0331, respectively). However, treatment with the combination MFG with FLC improved the survival rate only compared with that for the con- All the experiments were performed as a single study with the exception of the combined therapy against strain IHEM 17911, which was done separately. In this case the experiment with the control group was repeated to confirm the reproducibility of the results, and the curve is the result of the mean for both data sets. trol group (P ϭ 0.0136). Among the monotherapies, only AMB was able to increase the rate of survival in comparison to that for the control group (P ϭ 0.0245). In addition, in experiments with both strains, the rate of survival obtained with FLC or MFG alone was no different from that for the control group. The livers, spleens, and kidneys of mice infected with T. asahii IHEM 17910 and not treated showed high fungal loads (Table 3 ). The organ most affected was the kidney. Both combinations, MFG with AMB and MFG with FLC, significantly reduced the organism burdens in kidney tissue with respect to those achieved with the monotherapies (P Ͻ 0.05) and in the control group (P Ͻ 0.001). Only AMB and the combination MFG with AMB were able to reduce significantly the organism burden in liver tissue compared with that in the liver tissue of the control group (P Ͻ 0.05). The two combination regimens and MFG alone were all able to reduce significantly the fungal load in the spleen in comparison to that in the spleen of the control group (P Ͻ 0.05). Histological studies revealed that conidial and hyphal elements diffusely infiltrated all the organs examined (Fig. 3) . Little inflammatory response appeared in any of the lesions that developed as a result of infection with either strain, and no remarkable differences in the inflammatory responses to the two strains were found. While the organs of infected mice treated with monotherapies showed numerous fungal elements, these were practically absent from the organs of mice treated with the combination therapies.
DISCUSSION
We have established a murine model of disseminated trichosporonosis using two strains of T. asahii. The rates of survival were practically identical among the mice infected with each of the two strains and were very similar to those reported by other investigators (2, 15) , although the immunosuppression regimens used in the two studies were different, as were probably the mouse species tested. The lack of efficacy of AMB and FLC observed in our study when they were administrated alone agrees with clinical data that show that, despite treatment with such drugs, approximately 80% of patients die (9) . Improvement in the neutropenic state of patients with disseminated trichosporonosis implies a better prognosis for their recovery, although it is not always sufficient to cure the infections, and antifungal treatment is also required (9, 23) . The best strategy for the treatment of severe trichosporonosis is not yet clearly defined (9) . In persistently neutropenic patients the use of FLC or the combination FLC with AMB has been recommended (10, 23) , even though in some cases treatments fail (9) . In our study, although the MICs of AMB and FLC were not high and the strains could have been considered susceptible to the two drugs, the effectiveness of these drugs was poor in vivo. For this reason it is very important to have reliable therapeutic alternatives. Some recent data seem to emphasize this need. A recent study (24) reported on T. asahii strains that infected nongranulocytopenic patients in different intensive care units for which AMB MICs were 2 to Ͼ32 g/ml and FLC MICs were 32 to 128 g/ml. In the present study the activity of FLC was not superior to that of AMB, and the MFG MIC for the two strains of T. asahii tested was high, which also agrees with the low survival rate of mice treated with this antifungal drug. Although MFG is considered intrinsically inactive against Trichosporon spp. (6) , when it was combined with AMB in our study, it was able to prolong significantly the MST in compar- ison to those achieved with the monotherapies and for the control group. This combination was able to reduce significantly the fungal loads in the three organs studied in comparison with the loads in the controls and, in addition, was able to reduce the burdens in kidney tissues, the organ most affected by the fungi, with respect to those achieved with the monotherapies. It is possible that a more marked reduction would be achieved with a longer treatment. The actual mechanism that explains the positive interaction between MFG and AMB is unclear. Arikan et al. (3) found a similar effect between another echinocandin, caspofungin, and AMB when they tested clinical isolates of Aspergillus and Fusarium in vitro. They concluded that the echinocandin could enhance the penetration of AMB into the cell membrane, causing the decrease in the AMB MICs. However, how the echinocandin MICs are lowered when the drug is used in combination with AMB is more difficult to explain. The other combination, MFG with FLC, was able to prolong significantly the MST only with respect to that for the control group. None of the regimens tested was able to sterilize any organ, similarly to that happened with the combination FLC with AMB tested by other investigators (2, 15) , probably due to the short duration of the therapy.
MFG is effective against systemic trichosporonosis when it is given in combination with AMB or FLC, although only the combination MFG plus AMB shows synergistic effects. Further studies are warranted to determine the optimal treatment regimens that might potentially result in cures.
